Results 51 to 60 of about 688 (142)

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, Volume 174, Issue 3, Page 1151-1171, September 2026.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Multimodal Cross‐Attentive Graph‐Based Framework for Predicting In Vivo Endocrine Disruptors

Advanced Science, Volume 13, Issue 21, 13 April 2026.
A multimodal cross‐attentive graph neural network integrates molecular graphs with androgen and estrogen adverse outcome pathway (AOP)–anchored in vitro assay signals to predict in vivo endocrine disruption. By fusing information on Tier‐1 AOP logits with chemical structures, the framework achieves high accuracy and provides assay‐traceable ...
Eder Soares de Almeida Santos, Gustavo Felizardo Santos Sandes, Artur Christian Garcia da Silva, Holli‐Joi Martin, Eugene N. Muratov, Rodolpho de Campos Braga, Bruno Junior Neves   +6 more
wiley   +1 more source

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

, 2014
OBJECTIVE: Assessment of 12-month safety of ospemifene 60 mg/day for treatment of postmenopausal women with vulvar and vaginal atrophy (VVA).METHODS: In this 52-week, randomized, double-blind, placebo-controlled, parallel-group study, women 40-80 years ...
Portman, D J, Lin, V H, Blaakær, Jan; id_orcid, Goldstein, S R, Koninckx, P R, Ylikorkala, O, Bachmann, G A, Ravn, Pernille; id_orcid   +7 more
core   +1 more source

Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up.

, 2022
20.500.12530/87852To assess the improvement in vulvovaginal atrophy (VVA) of postmenopausal women treated with oral ospemifene 60 mg/day under conditions of routine clinical practice after 12 months of follow-up.
Lafuente González, Pilar, Palacios, Santiago, Calvente Aguilar, Virginia, Pingarrón Santofímia, Carmen, Guitiérrez Vélez, María Del Carmen, Poyo Torcal, Silvia, Terol Sánchez, Pablo   +6 more
core   +1 more source

Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer remains a major global public health problem. A key aspect of cancer care among survivors is sexual health. Cancer patients experience a range of sexual dysfunctions, including erectile dysfunction, vaginal dryness, dyspareunia, and reduced libido.
Pasquale Marino, Roberta Colangelo, Paola Amendola, Ilaria Bochicchio, Alessandro Rocco Lettini, Stefania Lapadula, Alda Giuliano, Martina Catalano, Francesca Sanseverino   +8 more
wiley   +1 more source

Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals

Advanced Functional Materials, Volume 36, Issue 16, 23 February 2026.
This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee, Sojin Kim, Myeongeun Lee, Kyoungsuk Jin, Jimin Park   +4 more
wiley   +1 more source

Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo

, 2013
The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism.
Miia Turpeinen, Risto Lammintausta, Jouko Uusitalo, Olavi Pelkonen, Mika Scheinin, Terhi Lehtinen, Camilla Stjernschantz, Pasi Tapanainen, Marita Kailajärvi, Jouni Vuorinen   +9 more
core   +1 more source

Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.

, 2018
INTRODUCTION: Vulvo-vaginal atrophy affects the daily lives of most post-menopausal women. We know that ospemifene intake can induce vaginal epithelial improvements within a few weeks; however, direct evidence of the effects of ospemifene on the human ...
Alvisi S, Meriggiola MC, Seracchioli R, Gava G, Mancini I, Baldassarre M, Gagliardi M   +6 more
core   +1 more source

Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper

International Journal of Gynecology &Obstetrics, Volume 164, Issue 2, Page 516-530, February 2024.
Abstract Menopause marks the end of menstrual cyclicity and, depending on individual vulnerability, has several consequences related to gonadal steroid deprivation, especially if it is premature. Menopause may be more burdensome for some women than for others.
Andrea R. Genazzani, Hema Divakar, Suvarna S. Khadilkar, Patrizia Monteleone, Bernadette Evangelisti, Ahmed F. Galal, Paola I. R. Priego, Tommaso Simoncini, Andrea Giannini, Gelila Goba, Chiara Benedetto   +10 more
wiley   +1 more source

Ospemifene Hormos

, 2004
Hormos Medical is developing the selective estrogen receptor modulator ospemifene, for the potential treatment of postmenopausal osteoporosis and urogenital atrophy.
GENNARI, LUIGI
core   +1 more source